{"id":49685,"date":"2022-06-21T12:00:00","date_gmt":"2022-06-21T17:00:00","guid":{"rendered":"https:\/\/www.tradestation.io\/insights\/?p=49685"},"modified":"2022-06-23T09:38:08","modified_gmt":"2022-06-23T14:38:08","slug":"united-therapeutics-technical-analysis-bullish","status":"publish","type":"post","link":"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/","title":{"rendered":"Chart of the Day: This Drug Developer Rallied and Now It’s Pulled Back"},"content":{"rendered":"\n

United Therapeutics spent more than a year consolidating around its 2015 highs. Now the biotech may be attempting a breakout.<\/p>\n\n\n\n

Notice the surge to new all-time highs late last month. The rally followed news that the Food & Drug Administration approved its Tyvaso DPI hypertension drug for two applications. (There were worries of a narrower approval.)<\/p>\n\n\n\n

UTHR paused for about three weeks and pulled back toward $215. That level is …<\/p>\n\n\n\n

For more, please\u00a0click\u00a0here\u00a0<\/a>to view the related idea and chart analysis on\u00a0TradingView<\/a>.<\/em><\/p>\n\n\n\n

\"\"\/
United Therapeutics (UTHR), daily chart with selected patterns and indicators, courtesy of TradingView<\/em>.<\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"

United Therapeutics spent more than a year consolidating around its 2015 highs. Now the biotech may be attempting a breakout. Notice the surge to new all-time highs late last month. The rally followed news that the Food & Drug Administration approved its Tyvaso DPI hypertension drug for two applications. (There were worries of a narrower […]<\/p>\n","protected":false},"author":39,"featured_media":49688,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[32,13,38],"tags":[1245],"yoast_head":"\nChart of the Day: This Drug Developer Rallied and Now It's Pulled Back | Market Insights<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chart of the Day: This Drug Developer Rallied and Now It's Pulled Back | Market Insights\" \/>\n<meta property=\"og:description\" content=\"United Therapeutics spent more than a year consolidating around its 2015 highs. Now the biotech may be attempting a breakout. Notice the surge to new all-time highs late last month. The rally followed news that the Food & Drug Administration approved its Tyvaso DPI hypertension drug for two applications. (There were worries of a narrower […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Insights\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeStation\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-21T17:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-23T14:38:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/uploads.tradestation.com\/uploads\/sites\/2\/heart-lungs-AdobeStock_305833632-scaled-e1655994200787.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1523\" \/>\n\t<meta property=\"og:image:height\" content=\"857\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"David Russell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeStation\" \/>\n<meta name=\"twitter:site\" content=\"@TradeStation\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"David Russell\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/\",\"url\":\"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/\",\"name\":\"Chart of the Day: This Drug Developer Rallied and Now It's Pulled Back | Market Insights\",\"isPartOf\":{\"@id\":\"https:\/\/www.tradestation.com\/insights\/#website\"},\"datePublished\":\"2022-06-21T17:00:00+00:00\",\"dateModified\":\"2022-06-23T14:38:08+00:00\",\"author\":{\"@id\":\"https:\/\/www.tradestation.com\/insights\/#\/schema\/person\/d2279ba57f90e3b47887f2503ce142d4\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.tradestation.com\/insights\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chart of the Day: This Drug Developer Rallied and Now It’s Pulled Back\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.tradestation.com\/insights\/#website\",\"url\":\"https:\/\/www.tradestation.com\/insights\/\",\"name\":\"Market Insights\",\"description\":\"Fresh market commentary and actionable trade ideas.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.tradestation.com\/insights\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.tradestation.com\/insights\/#\/schema\/person\/d2279ba57f90e3b47887f2503ce142d4\",\"name\":\"David Russell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.tradestation.com\/insights\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/443bdca82f0006231c5179581e4310ed?s=96&d=mm&r=pg\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/443bdca82f0006231c5179581e4310ed?s=96&d=mm&r=pg\",\"caption\":\"David Russell\"},\"description\":\"David Russell is VP of Market Intelligence at TradeStation Group. Drawing on two decades of experience as a financial journalist and analyst, his background includes equities, emerging markets, fixed-income and derivatives. He previously worked at Bloomberg News, CNBC and E*TRADE Financial. Russell systematically reviews countless global financial headlines and indicators in search of broad tradable trends that present opportunities repeatedly over time. Customers can expect him to keep them apprised of sector leadership, relative strength and the big stories \u2013 especially those overlooked by other commentators. He\u2019s also a big fan of generating leverage with options to limit capital at risk.\",\"url\":\"https:\/\/www.tradestation.com\/insights\/author\/drussell\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chart of the Day: This Drug Developer Rallied and Now It's Pulled Back | Market Insights","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/","og_locale":"en_US","og_type":"article","og_title":"Chart of the Day: This Drug Developer Rallied and Now It's Pulled Back | Market Insights","og_description":"United Therapeutics spent more than a year consolidating around its 2015 highs. Now the biotech may be attempting a breakout. Notice the surge to new all-time highs late last month. The rally followed news that the Food & Drug Administration approved its Tyvaso DPI hypertension drug for two applications. (There were worries of a narrower […]","og_url":"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/","og_site_name":"Market Insights","article_publisher":"https:\/\/www.facebook.com\/TradeStation\/","article_published_time":"2022-06-21T17:00:00+00:00","article_modified_time":"2022-06-23T14:38:08+00:00","og_image":[{"width":1523,"height":857,"url":"https:\/\/uploads.tradestation.com\/uploads\/sites\/2\/heart-lungs-AdobeStock_305833632-scaled-e1655994200787.jpeg","type":"image\/jpeg"}],"author":"David Russell","twitter_card":"summary_large_image","twitter_creator":"@TradeStation","twitter_site":"@TradeStation","twitter_misc":{"Written by":"David Russell","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/","url":"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/","name":"Chart of the Day: This Drug Developer Rallied and Now It's Pulled Back | Market Insights","isPartOf":{"@id":"https:\/\/www.tradestation.com\/insights\/#website"},"datePublished":"2022-06-21T17:00:00+00:00","dateModified":"2022-06-23T14:38:08+00:00","author":{"@id":"https:\/\/www.tradestation.com\/insights\/#\/schema\/person\/d2279ba57f90e3b47887f2503ce142d4"},"breadcrumb":{"@id":"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.tradestation.com\/insights\/2022\/06\/21\/united-therapeutics-technical-analysis-bullish\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.tradestation.com\/insights\/"},{"@type":"ListItem","position":2,"name":"Chart of the Day: This Drug Developer Rallied and Now It’s Pulled Back"}]},{"@type":"WebSite","@id":"https:\/\/www.tradestation.com\/insights\/#website","url":"https:\/\/www.tradestation.com\/insights\/","name":"Market Insights","description":"Fresh market commentary and actionable trade ideas.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.tradestation.com\/insights\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.tradestation.com\/insights\/#\/schema\/person\/d2279ba57f90e3b47887f2503ce142d4","name":"David Russell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.tradestation.com\/insights\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/443bdca82f0006231c5179581e4310ed?s=96&d=mm&r=pg","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/443bdca82f0006231c5179581e4310ed?s=96&d=mm&r=pg","caption":"David Russell"},"description":"David Russell is VP of Market Intelligence at TradeStation Group. Drawing on two decades of experience as a financial journalist and analyst, his background includes equities, emerging markets, fixed-income and derivatives. He previously worked at Bloomberg News, CNBC and E*TRADE Financial. Russell systematically reviews countless global financial headlines and indicators in search of broad tradable trends that present opportunities repeatedly over time. Customers can expect him to keep them apprised of sector leadership, relative strength and the big stories \u2013 especially those overlooked by other commentators. He\u2019s also a big fan of generating leverage with options to limit capital at risk.","url":"https:\/\/www.tradestation.com\/insights\/author\/drussell\/"}]}},"_links":{"self":[{"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/posts\/49685"}],"collection":[{"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/users\/39"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/comments?post=49685"}],"version-history":[{"count":6,"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/posts\/49685\/revisions"}],"predecessor-version":[{"id":49692,"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/posts\/49685\/revisions\/49692"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/media\/49688"}],"wp:attachment":[{"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/media?parent=49685"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/categories?post=49685"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tradestation.com\/insights\/wp-json\/wp\/v2\/tags?post=49685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}